Trial Profile
A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Vorinostat (Primary)
- Indications Head and neck cancer; Salivary gland cancer; Squamous cell cancer
- Focus Adverse reactions
- 16 Oct 2023 Status changed from active, no longer recruiting to completed.
- 16 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 01 Feb 2023 Results reporting safety and efficacy data published in the Head and Neck